...

Mireia Arnedo Valero Referències REFERÈNCIES

by user

on
1

views

Report

Comments

Transcript

Mireia Arnedo Valero Referències REFERÈNCIES
Mireia Arnedo Valero
Referències
REFERÈNCIES
st
Adams B, Holte S, Randolph T, Banks HT. STI control of HIV infection. 1 SIAM
Conference on the Life Sciences. Boston, USA. March 2002.
Alcami J, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F,
Noriega AR, Hay RT, Harrich D, Gaynor RB, et al.
Absolute dependence on kappa B responsive elements for initiation and Tatmediated amplification of HIV transcription in blood CD4 T lymphocytes.
EMBO J. 1995 Apr 3;14(7):1552-60.
Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge
RL ,and al. Cellular immune responses and viral diversity in individuals treated
during acute and early HIV-1 infection. J Exp Med 2001, 15; 193(2): 169-80.
Allain JP, Laurian Y, Paul DA, Senn D.
Serological markers in early stages of human immunodeficiency virus infection in
haemophiliacs.
Lancet. 1986 Nov 29;2(8518):1233-6.
Allain JP, Frommel D, Bosser C, Gazengel C, Larrieu MJ, Sultan Y.
The role of HIV infectivity and composition of factor VIII concentrates on the
immunity of haemophiliacs positive for HIV antibodies.
Vox Sang. 1987;53(1):37-43.
Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo
EM.
Replicative capacity of human immunodeficiency virus from patients with varying
severity of HIV infection.
Lancet. 1986 Sep 20;2(8508):660-2.
Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre
P, Leibowitch J.
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis
and function in advanced HIV disease.
Science. 1997 Jul 4;277(5322):112-6.
Autran B, Carcelain G.
AIDS. Boosting immunity to HIV--can the virus help?
Science. 2000 Nov 3;290(5493):946-9.
Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral
management based on plasma genotypic antiretroviral resistance testing in
patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community
Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-F93.
Bagglioni M, Dewald B, Moser B. Interleukin 8 and related chemotactic cytokines
CXC and CC chemokines. Adv Immunol 1994; 55:97-179.
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J,
Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W,
Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for
169
Mireia Arnedo Valero
Referències
acquired
immune
deficiency
Science. 1983 May 20;220(4599):868-71.
syndrome
(AIDS).
Berger EA, Murphy PM, Farber JM.
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and
disease. Annu Rev Immunol. 1999;17:657-700
Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, Kwok S, Louie
L, Eron J, Sheppard H, Frelinger JA.
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is
inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term
survivors. AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1219-28.
Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP.
The relationship between T cell proliferative responses and plasma viremia during
treatment of human immunodeficiency virus type 1 infection with combination
antiretroviral therapy.
J Infect Dis. 2000 Apr;181(4):1249-63. Epub 2000 Apr 13.
Blankson JN, Persaud D, Siliciano RF.
The challenge of viral reservoirs in HIV-1 infection.
Annu Rev Med. 2002;53:557-93
Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA.
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks
HIV-1 entry. Nature. 1996 Aug 29;382(6594):829-33.
Boden D, Hurley A, Zhan L, et al. HIV-1 drug resistancein newly infected individuals.
J Am Med Association 1999; 282:1135-1141
Bofill M, Gombert W, Borthwick NJ, Akbar AN, McLaughlin JE, Lee CA, Johnson
MA, Pinching AJ, Janossy G. Presence of CD3+CD8+Bcl-2(low) lymphocytes
undergoing apoptosis and activated macrophages in lymph nodes of HIV-1+
patients. Am J Pathol. 1995 Jun;146(6):1542-55.
Bollinger RC Jr, Kline RL, Francis HL, Moss MW, Bartlett JG, Quinn TC.
Acid dissociation increases the sensitivity of p24 antigen detection for the
evaluation of antiviral therapy and disease progression in asymptomatic human
immunodeficiency virus-infected persons. J Infect Dis. 1992 May;165(5):913-6.
Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF.
Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1
infection. AIDS. 2000 Oct 20;14(15):2313-22.
Boucher CA, O’Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine
resistance mutations during treatment of 18 HIV-positive subjects. J Infect Dis 1992;
165:105-110
Boucher CA, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD,
Schipper P, Back NKHuman immunodeficiency virus type 1 drug susceptibility
determination by using recombinant viruses generated from patient sera tested in
a cell-killing assay. Antimicrob Agents Chemother 1996 Oct;40(10):2404-9.
170
Mireia Arnedo Valero
Referències
Boulmé R, Halfon P, Diaz R, et al. Comparative evaluation between five automated
resistance interpretation algoritms. Antiviral Ther 2001; 6(suppl 1):121
Bouscarat F, Levacher M, Dazza MC, Chau F, Desforges B, Muffat-Joly M,
Matheron S, Girard PM, Sinet M.
Prospective study of CD8+ lymphocyte activation in relation to viral load in HIVinfected patients with > or = 400 CD4+ lymphocytes per microliter.
AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1419-25.
Briones C, Rodríguez C, Del Romero J, et al. Primary genotypic and phenotypic
resistance to antiretroviral drugs in recent seroconverters in Madrid. J Acquir
Immune Defic Syndr 2001; 26:145-150
Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW.
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection.
Ann Neurol. 1990 Oct;28(4):556-60.
Brunet M, Oppenheimer F, Martorell J, Vilardell J, Carreno MC, Carrillo M,
Corbella J. Mycophenolic acid monitoring: evaluation of the EMIT MPA
immunoassay in kidney and lung transplantation. Transplant Proc. 1999
Sep;31(6):2275-6.
Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millan O, Carrillo M, Rojo I,
Corbella J. Pharmacokinetics and pharmacodynamics of mycophenolic acid in
stable renal transplant recipients treated with low doses of mycophenolate
mofetil. Transpl Int. 2000;13 Suppl 1:S301-5.
Bubrinsky MI, Stanwick L, Demsey MP, et al. Quiescent T Lymphocytes as an
inducible virus reservoir of HIV-1 infection. Science 1991; 254: 423-7.
Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD.
Long-term HIV-1 infection without immunologic progression. AIDS. 1994
Aug;8(8):1123-8.
Buchbinder S, Vittinghoff E.
HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed
progression, and clinical and research implications. Microbes Infect. 1999
Nov;1(13):1113-20.
Busch MP, Operskalski EA, Mosley JW, Lee TH, Henrard D, Herman S, Sachs
DH, Harris M, Huang W, Stram DO.
Factors influencing human immunodeficiency virus type 1 transmission by blood
transfusion. Transfusion Safety Study Group.
J Infect Dis. 1996 Jul;174(1):26-33.
Bushman F.
Measuring covert HIV replication during HAART: the abundance of 2-LTR circles
is not a reliable marker.
AIDS. 2003 Mar 28;17(5):749-50.
Butto S, Argentini C, Mazzella AM, Iannotti MP, Leone P, Leone P, Nicolosi A,
Rezza G. Dual infection with different strains of the same HIV-1 subtype.
AIDS. 1997 Apr;11(5):694-6.
171
Mireia Arnedo Valero
Referències
Cabana M, Clotet B, Martinez MA.
Emergence and genetic evolution of HIV-1 variants with mutations conferring
resistance to multiple reverse transcriptase and protease inhibitors.
J Med Virol. 1999 Dec;59(4):480-90.
Cann AJ, Karn J.
Molecular biology of HIV: new
AIDS. 1989;3 Suppl 1:S19-34. Review.
insights
into
the
virus
life-cycle.
Cao J, McNevin J, Malhotra U, McElrath MJ. Evolution of CD8+ T cell immunity
and viral escape following acute HIV-1 infection. J Immunol. 2003 Oct
1;171(7):3837-46.
Cao YZ, Valentine F, Hojvat S, Allain JP, Rubinstein P, Mirabile M, Czelusniak S,
Leuther M, Baker L, Friedman-Kien AE.
Detection of HIV antigen and specific antibodies to HIV core and envelope
proteins in sera of patients with HIV infection. Blood. 1987 Aug;70(2):575-8.
Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, Katlama C,
Autran B.
Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 Thelper cells fails to control virus rebounds during intermittent antiretroviral therapy
in chronic HIV type 1 infection. J Virol. 2001 Jan;75(1):234-41.
Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein
DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S,
Yeni PG, Volberding PA.
Antiretroviral therapy for HIV infection in 1996. Recommendations of an
international panel. International AIDS Society-USA. JAMA. 1996 Jul
10;276(2):146-54.
Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein
DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S,
Yeni PG, Volberding PA.
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the
International AIDS Society-USA panel. JAMA. 1997 Jun 25;277(24):1962-9.
Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM,
Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS,
Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA.
Antiretroviral therapy in adults: updated recommendations of the International
AIDS Society-USA Panel. JAMA. 2000 Jan 19;283(3):381-90.
Carrillo A, Ratner L.
Cooperative effects of the human immunodeficiency virus type 1 envelope
variable loops V1 and V3 in mediating infectivity for T cells.
J Virol. 1996 Feb;70(2):1310-6.
Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K,
Henry K, Zhang ZQ, Mills R, McDade H, Schuwirth CM, Goudsmit J, Danner SA,
Haase AT.
172
Mireia Arnedo Valero
Referències
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1
infection. Science. 1997 May 9;276(5314):960-4.
Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T,
Craft JC, Sattler FR.
Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A
randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical
Trials Group Protocol 157 Study Team. Ann Intern Med. 1994 Dec
15;121(12):905-11.
Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled
coil
of
HIV
type
1
gp41
is
an
attractive
drug
target.
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15613-7.
Chapuis AG, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury
S, Acha-Orbea H, Pantaleo G.
Effects of mycophenolic acid on human immunodeficiency virus infection in vitro
and in vivo. Nat Med. 2000 Jul;6(7):762-8.
Cheng-Mayer C, Seto D, Tateno M, Levy JA.
Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988
Apr 1;240(4848):80-2.
Cheng-Mayer C, Weiss C, Seto D, Levy JA.
Isolates of human immunodeficiency virus type 1 from the brain may constitute a
special group of the AIDS virus. Proc Natl Acad Sci U S A. 1989
Nov;86(21):8575-9.
Chen Y, Rinaldo C, Gupta P.
A semiquantitative assay for CD8+ T-cell-mediated suppression of human
immunodeficiency
virus
type
1
infection.
Clin Diagn Lab Immunol. 1997 Jan;4(1):4-10.
Cheingsong-Popov R, Callow D, Beddows S, Shaunak S, Wasi C, Kaleebu P,
Gilks C, Petrascu IV, Garaev MM, Watts DM, et al.
Geographic diversity of human immunodeficiency virus type 1: serologic reactivity
to env epitopes and relationship to neutralization.
J Infect Dis. 1992 Feb;165(2):256-61.
Chesebro B, Wehrly K, Nishio J, Perryman S.
Mapping of independent V3 envelope determinants of human immunodeficiency
virus type 1 macrophage tropism and syncytium formation in lymphocytes.
J Virol. 1996 Dec;70(12):9055-9.
Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW.
Self-reported adherence to antiretroviral medications among participants in HIV
clinical trials: the AACTG adherence instruments. Patient Care Committee &
Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical
Trials Group (AACTG). AIDS Care. 2000 Jun;12(3):255-66.
Chess Q, Daniels J, North E, Macris NT.
Serum immunoglobulin elevations in the acquired immunodeficiency syndrome
(AIDS): IgG, IgA, IgM, and IgD. Diagn Immunol. 1984;2(3):148-53.
173
Mireia Arnedo Valero
Referències
Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR,
LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J.
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary
HIV-1 isolates. Cell. 1996 Jun 28;85(7):1135-48.
Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo
fate of HIV-1-infected T cells: quantitative analysis of the transition to stable
latency. Nat Med. 1995 Dec;1(12):1284-90.
Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak
MA, Fauci AS.
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral
therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7.
Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS.
Early establishment of a pool of latently infected, resting CD4(+) T cells during
primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73.
Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey RT Jr,
Dybul M, Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci
AS. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in
HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med.
1999 Jun;5(6):651-5.
Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI,
Fauci AS.
Relationship between pre-existing viral reservoirs and the re-emergence of
plasma viremia after discontinuation of highly active anti-retroviral therapy.
Nat Med. 2000 Jul;6(7):757-61.
Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ,
Kappes JC, Hahn BH, Shaw GM.
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV1 infection. N Engl J Med. 1991 Apr 4;324(14):954-60
Clark RA, Brandon W, Dumestre J, Pindaro C.
Clinical manifestations of infection with the human immunodeficiency virus in
women in Louisiana. Clin Infect Dis. 1993 Aug;17(2):165-72.
Clarke DK, Duarte EA, Elena SF, Moya A, Domingo E, Holland J.
The red queen reigns in the kingdom of RNA viruses.
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4821-4.
Clavel F, Brun-Vezinet F, Guetard D, Chamaret S, Laurent A, Rouzioux C, Rey
M, Katlama C, Rey F, Champelinaud JL, et al. LAV type II: a second retrovirus
associated with AIDS in West Africa. C R Acad Sci III. 1986;302(13):485-8.
French.
Coffin JM.
HIV population dynamics in vivo: implications for genetic variation, pathogenesis,
and therapy. Science. 1995 Jan 27;267(5197):483-9.
174
Mireia Arnedo Valero
Referències
Cohen OJ, Vaccarezza M, Lam GK, Baird BF, Wildt K, Murphy PM, Zimmerman
PA, Nutman TB, Fox CH, Hoover S, Adelsberger J, Baseler M, Arthos J, Davey
RT Jr, Dewar RL, Metcalf J, Schwartzentruber DJ, Orenstein JM, Buchbinder S,
Saah AJ, Detels R, Phair J, Rinaldo C, Margolick JB, Fauci AS, et al.
Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole
determinant for the immunologic and virologic phenotype of HIV-infected longterm nonprogressors. J Clin Invest. 1997 Sep 15;100(6):1581-9.
Cohen C, Kessler H, Hunt S, et al. Phenotypic resistance testing significantly
improves response to therapy: final analysis of a randomized trial (VIRA3001 ).
Antivir Ther. 2000;5(suppl 3):67.
Cohen DE, Walker BD.
Human immunodeficiency virus pathogenesis and prospects for immune control
in patients with established infection. Clin Infect Dis. 2001 Jun 15;32(12):1756-68.
Epub 2001 May 16.
Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC,
Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al.
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.
Nature. 1995 Apr 6;374(6522):569-71.
Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ,
Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash
M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW,
Squires KE, Steigbigel RT, Teppler H, Emini EA.
Genetic correlates of in vivo viral resistance to indinavir, a human
immunodeficiency virus type 1 protease inhibitor. J Virol. 1996 Dec;70(12):82706.
Connor RI, Mohri H, Cao Y, Ho DD.
Increased viral burden and cytopathicity correlate temporally with CD4+ Tlymphocyte decline and clinical progression in human immunodeficiency virus
type 1-infected individuals. J Virol. 1993 Apr;67(4):1772-7.
Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor
use coreceptor use correlates with disease progression in HIV-1--infected
individuals. J Exp Med. 1997 Feb 17;185(4):621-8.
Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ,
Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB,
DeGruttola V, Crumpacker CS, Kahn J.
Association of plasma human immunodeficiency virus type 1 RNA level with risk
of clinical progression in patients with advanced infection. AIDS Clinical Trials
Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance
and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct;174(4):704-12.
Cullen BR, Garrett ED.
A
comparison
of
regulatory
features
in
primate
AIDS Res Hum Retroviruses. 1992 Mar;8(3):387-93. Review.
175
lentiviruses.
Mireia Arnedo Valero
Referències
Cullen BR
HIV-1
auxiliary
proteins:
making
Cell. 1998 May 29;93(5):685-92. Review.
connections
in
a
dying
cell.
Daar ES, Moudgil T, Meyer RD, Ho DD.
Transient high levels of viremia in patients with primary human immunodeficiency
virus type 1 infection. N Engl J Med. 1991 Apr 4;324(14):961-4.
D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V,
Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, et al.
Zidovudine resistance and HIV-1 disease progression during antiretroviral
therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology
Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15;122(6):4018.
Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert
JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R,
Saah A, Rinaldo C, Detels R, O'Brien SJ.
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele
of the CKR5 structural gene. Hemophilia Growth and Development Study,
Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San
Francisco City Cohort, ALIVE Study. Science. 1996 Sep 27;273(5283):1856-62.
de Jong MD, de Boer RJ, de Wolf F, Foudraine NA, Boucher CA, Goudsmit J,
Lange JM.
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
AIDS. 1997 Sep;11(11):F79-84.
de Santis C, Lopalco L, Robbioni P, Longhi R, Rappocciolo G, Siccardi AG,
Beretta A.
Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with
HLA class I on activated cells. AIDS Res Hum Retroviruses. 1994 Feb;10(2):15762.
Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS,
Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM.
Virologic and immunologic consequences of discontinuing combination
antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl
J Med. 2001 Feb 15;344(7):472-80.
Deeks SG, Barditch-Crovo P, Collier A, Smith A, Miller M, McGowan I, Coakley
DF. Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir
disoproxil fumarate. J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):336-9.
DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S,
Hollinger FB, Fischl MA, Volberding P.
Serum p24 antigen level as an intermediate end point in clinical trials of
zidovudine in people infected with human immunodeficiency virus type 1. Aids
Clinical Trials Group Virology Laboratories. J Infect Dis. 1994 Apr;169(4):713-21.
Delassus S, Cheynier R, Wain-Hobson S.
Nonhomogeneous distribution of human immunodeficiency virus type 1
proviruses in the spleen. J Virol. 1992 Sep;66(9):5642-5.
176
Mireia Arnedo Valero
Referències
Delwart EL
Human immunodeficiency virus type 1 evolution in vivo tracked by DNA
heteroduplex mobility assays. J Virol. 1994 Oct;68(10):6672-83.
Delwart EL, Gordon CJ.
Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex
analysis. Methods. 1997 Aug;12(4):348-54.
Delwart EL, Pan H, Neumann A, Markowitz M.
Rapid, transient changes at the env locus of plasma human immunodeficiency
virus type 1 populations during the emergence of protease inhibitor resistance.
J Virol. 1998 Mar;72(3):2416-21.
Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J,
Holden-Wiltse J, Greisberger C, Wood K, Timpone J Jr, Wathen LK, Nevin T,
Resnick L, Batts DH, Reichman RC. Phase I study of atevirdine mesylate (U87201E) monotherapy in HIV-1-infected patients. J Acquir Immune Defic Syndr
Hum Retrovirol. 1998 Oct 1;19(2):135-44.
Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P,
Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR,
Landau NR. Identification of a major co-receptor for primary isolates of HIV-1.
Nature. 1996 Jun 20;381(6584):661-6.
Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw
GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to fusion
inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41
and is consistently modulated by gp120 interactions with the coreceptor. J Virol.
2001 Sep;75(18):8605-14.
Descamps D, Flandre P, calvez V, et al. Mechanisms of virologic failure in
previously untreated HIV-infected patients from a trial of induction-maintenance
therapy. JAMA 2000; 283:205-211
Devereux HL, Youle M, Johnson MA, Loveday C.
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping
therapy. AIDS. 1999 Dec 24;13(18):F123-7.
Domingo E, Menendez-Arias L, Quinones-Mateu ME, Holguin A, Gutierrez-Rivas
M, Martinez MA, Quer J, Novella IS, Holland JJ.
Viral quasispecies and the problem of vaccine-escape and drug-resistant
mutants. Prog Drug Res. 1997;48:99-128.
Domingo E, Mas A, Yuste E, Pariente N, Sierra S, Gutierrez-Riva M, MenendezArias L. Virus population dynamics, fitness variations and the control of viral
disease: an update. Prog Drug Res. 2001;57:77-115.
Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M,
Collman RG, Doms RW.
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine
receptors
CKR-5,
CKR-3,
and
CKR-2b
as
fusion
cofactors.
Cell. 1996 Jun 28;85(7):1149-58.
177
Mireia Arnedo Valero
Referències
Dorman KS, Kaplan AH, Lange K, Sinsheimer JS.
Mutation takes no vacation: can structured treatment interruptions increase the
risk of drug-resistant HIV-1?
J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):398-402.
Dorrucci M, Rezza G, Vlahov D, Pezzotti P, Sinicco A, Nicolosi A, Lazzarin A,
Galai N, Gafa S, Pristera R, et al.
Clinical characteristics and prognostic value of acute retroviral syndrome among
injecting drug users. Italian Seroconversion Study.
AIDS. 1995 Jun;9(6):597-604.
Doyon L, Croteau G, Thibeault D, et al. Second locus involved in HIV type 1
resistance to protease inhibitors. J Virol 1996; 70:3763-3769
Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan
C, Maddon PJ, Koup RA, Moore JP, Paxton WA.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Nature. 1996 Jun 20;381(6584):667-73.
Drake RR, Neamati N, Hong H, Pilon AA, Sunthankar P, Hume SD, Milne GW,
Pommier Y.
Identification of a nucleotide binding site in HIV-1 integrase.
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4170-5.
Drew WL, Anderson R, Lang W, Miner RC, Davis G, Lalezari J.
Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovirresistant CMV in HIV antibody positive patients.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):289-91.
Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1
therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195-2199.
Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar
RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT,
Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS.
Short-cycle structured intermittent treatment of chronic HIV infection with highly
active antiretroviral therapy: effects on virologic, immunologic, and toxicity
parameters.
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15161-6. Epub 2001 Dec 04.
Dybul M, Daucher M, Jensen MA, Hallahan CW, Chun TW, Belson M, Hidalgo B,
Nickle DC, Yoder C, Metcalf JA, Davey RT, Ehler L, Kress-Rock D, Nies-Kraske
E, Liu S, Mullins JI, Fauci AS.
Genetic characterization of rebounding human immunodeficiency virus type 1 in
plasma during multiple interruptions of highly active antiretroviral therapy.
J Virol. 2003 Mar;77(5):3229-37.
Escarmis C, Davila M, Charpentier N, Bracho A, Moya A, Domingo E.
Genetic lesions associated with Muller's ratchet in an RNA virus.
J Mol Biol. 1996 Nov 29;264(2):255-67.
178
Mireia Arnedo Valero
Referències
Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, Battegay M,
Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price
D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L,
Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study. A prospective trial of
structured treatment interruptions in human immunodeficiency virus infection.
Arch Intern Med. 2003 May 26;163(10):1220-6.
Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional
cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science.
1996 May 10;272(5263):872-7.
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn
TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD,
Richman DD, Siliciano RF.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral
therapy. Science. 1997 Nov 14;278(5341):1295-300.
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K,
Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B,
Gange S, Gallant J, Siliciano RF.
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of
HIV-1, even in patients on effective combination therapy. Nat Med. 1999
May;5(5):512-7.
Foli A, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, Lori F.
Therapeutic advantage of hydroxyurea and didanosine combination therapy in
patients previously treated with zidovudine. AIDS. 1998 Jun 18;12(9):1113-4.
Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS.
Tumor necrosis factor alpha induces expression of human immunodeficiency
virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A. 1989
Apr;86(7):2365-8.
Font E, Rosario O, Santana J, et al. Determination of zidovudine triphosphate
intracellular concentrations in peripheral blood mononuclear cells from HIVinfected individuals by tandem mass spectrometry. Antimicrob Agents Chemother
1999; 12:2964-2968
Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA,
Perelson AS, Wolinsky SM.
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in
patients receiving potent antiretroviral therapy. N Engl J Med. 1999 May
27;340(21):1614-22
Easterbrook PJ.
Non-progression in HIV infection. AIDS. 1994 Aug;8(8):1179-82.
Echaniz P, Arrizabalaga J, Iribarren JA, Cuadrado E.
CD8+CD38+ and CD8+DR+ peripheral blood lymphoid subsets of HIV-infected
intravenous drug abusers correlate with CD4+ cell counts and proliferation to
mitogens. Cell Immunol. 1993 Aug;150(1):72-80.
179
Mireia Arnedo Valero
Referències
Embretson J, Zupancic M, Beneke J, Till M, Wolinsky S, Ribas JL, Burke A,
Haase AT.
Analysis of human immunodeficiency virus-infected tissues by amplification and
in situ hybridization reveals latent and permissive infections at single-cell
resolution. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):357-61.
Emermam M, Malin MH. HIV-1 regulatory/accessory genes: keys to unravelling
viral and host cell biology. Science. 1998; 280: 1880-4.
Engelstad M.
Genetic diversity of env V3 loop sequences in HIV type 1-infected homosexuals,
heterosexuals, intravenous drug users, and hemophilia patients in norway: high
prevalence
of
subtype
B
and
detection
of
subtype
C.
AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1733-8.
Escaich S, Ritter J, Rougier P, Bizollon T, Lepot D, Lamelin JP, Sepetjan M,
Trepo C
HIV detection in culture of peripheral blood mononuclear cells: a relevant in vitro
correlate of the antiviral effect of ZDV in vivo. J Acquir Immune Defic Syndr.
1992;5(8):829-34.
Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, Battegay M,
Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price
D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L,
Plana M, Phillips R, Hirschel B; Swiss HIV Cohort Study.
A prospective trial of structured treatment interruptions in human
immunodeficiency virus infection. Arch Intern Med. 2003 May 26;163(10):1220-6.
Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV.
The prognostic value of cellular and serologic markers in infection with human
immunodeficiency virus type 1. N Engl J Med. 1990 Jan 18;322(3):166-72.
Fauci AS.
Optimal immunity to HIV--natural infection, vaccination, or both?
N Engl J Med. 1991 Jun 13;324(24):1733-5.
Feinberg MB, Jarrett RF, Aldovini A, Gallo RC, Wong-Staal F. HTLV-III
expression and production involve complex regulation at the levels of splicing and
translation of viral RNA. Cell. 1986 Sep 12;46(6):807-17.
Feng Y, Broder CC, Kennedy PE, Berger EA.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G
protein-coupled receptor. Science. 1996 May 10;272(5263):872-7.
Fenouillet E, Blanes N, Coutellier A, Demarquest J, Rozenbaum W, Gluckman
JC.
[Predictive value of the assay of serum anti-p25 antibodies in patients with human
immunodeficiency virus (HIV-1) infection]. Ann Med Interne (Paris).
1993;144(5):329-34.
Fenyo EM, Morfeldt-Manson L, Chiodi F, Lind B, von Gegerfelt A, Albert J,
Olausson E, Asjo B.
180
Mireia Arnedo Valero
Referències
Distinct replicative and cytopathic characteristics of human immunodeficiency
virus isolates. J Virol. 1988 Nov;62(11):4414-9.
Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C,Baba
TW, Ruprecht RM, Kupfer A.
Apoptosis occurs predominantly in bystander cells and not in productively
infected cells of HIV- and SIV-infected lymph nodes. Nat Med. 1995
Feb;1(2):129-34
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn
TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD,
Richman DD, Siliciano RF.
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral
therapy. Science. 1997 Nov 14;278(5341):1295-300.
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K,
Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B,
Gange S, Gallant J, Siliciano RF.
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of
HIV-1, even in patients on effective combination therapy. Nat Med. 1999
May;5(5):512-7.
Frade JM, Llorente M, Mellado M, Alcami J, Gutierrez-Ramos JC, Zaballos A,
Real G, Martinez-A C.
The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor
for HIV-1 infection. J Clin Invest. 1997 Aug 1;100(3):497-502.
Frost SD.
Dynamics and evolution of HIV-1 during structured treatment interruptions.
AIDS Rev. 2002 Jul-Sep;4(3):119-27.
Fuchs D, Unterweger B, Hausen A, Reibnegger G, Werner ER, Hengster P,
Hinterhuber H, Dierich MP, Wachter H, Blattner WA, et al.
Anti-HIV-1 antibodies, anti-HTLV-I antibodies and neopterin levels in parenteral
drug addicts in the Austrian Tyrol. J Acquir Immune Defic Syndr. 1988;1(1):65-6.
Furtado MR, Kingsley LA, Wolinsky SM.
Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+
T-cell number decline in human immunodeficiency virus type 1-infected
individuals. J Virol. 1995 Apr;69(4):2092-2100.
Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA,
Perelson AS, Wolinsky SM.
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in
patients receiving potent antiretroviral therapy. N Engl J Med. 1999 May
27;340(21):1614-22.
Gaines H, von Sydow M, Sonnerborg A, Albert J, Czajkowski J, Pehrson PO,
Chiodi F, Moberg L, Fenyo EM, Asjo B, et al.
Antibody response in primary human immunodeficiency virus infection.
Lancet. 1987 May 30;1(8544):1249-53.
181
Mireia Arnedo Valero
Referències
Gallaher WR, Ball JM, Garry RF, Griffin MC, Montelaro RC. A general model for
the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum
Retroviruses. 1989 Aug;5(4):431-40.
Ganeshan S, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM.
Human immunodeficiency virus type 1 genetic evolution in children with different
rates
of
development
of
disease.
J Virol. 1997 Jan;71(1):663-77.
Garcia F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent
JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T,
O'Brien WA, Miro JM, Gatell JM.
A randomized study comparing triple versus double antiretroviral therapy or no
treatment in HIV-1-infected patients in very early stage disease: the Spanish
Earth-1 study.
AIDS. 1999 Dec 3;13(17):2377-88.
Garcia F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D,
Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B,
Pumarola T, Gallart T, O'Brien WA, Miro JM, Gatell JM.
Comparison of immunologic restoration and virologic response in plasma,
tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with
double versus triple antiretroviral therapy in very early stages: The Spanish
EARTH-2 Study. Early Anti-Retroviral Therapy Study.
J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.
Gatell JM, Podzamczer D, Clotet B, Ocana I, Estany C, Figuerola M, Mariscal D.
[Incidence of infection with human immunodeficiency virus and acquired
immunodeficiency syndrome in a population from the Barcelona area]
Med Clin (Barc). 1988 Nov 26;91(18):681-4.
Gatell JM, Blanco JL, Alcamí J, et al. Documento de consenso de GESIDA sobre
la utilización de los estudios de resistencias en la práctica clínica. Enferm Infecc
Microbiol Clin 2001; 19:53-60
Gaynor R.
Cellular transcription factors involved in the regulation of HIV-1 gene
expression.AIDS. 1992 Apr;6(4):347-63. Review.
Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski
J, Morgado M, Galvao-Castro B, von Briesen H, et al.
Molecular cloning and analysis of functional envelope genes from human
immunodeficiency virus type 1 sequence subtypes A through G. The WHO and
NIAID Networks for HIV Isolation and Characterization. J Virol. 1996
Mar;70(3):1651-67.
Gazzard B.
The basics of antiretroviral prescribing.
J Infect. 1998 May;36(3):ii-iv.
Geels MJ, Cornelissen M, Schuitemaker H, Anderson K, Kwa D, Maas J, Dekker
JT, Baan E, Zorgdrager F, van den Burg R, van Beelen M, Lukashov VV, Fu TM,
Paxton WA, van der Hoek L, Dubey SA, Shiver JW, Goudsmit J. Identification of
182
Mireia Arnedo Valero
Referències
sequential viral escape mutants associated with altered T-cell responses in a
human immunodeficiency virus type 1-infected individual. J Virol. 2003
Dec;77(23):12430-40.
Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R.
Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic
value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles
Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1993
Aug;6(8):904-12.
Gomez-Cano M, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Soriano V, Pineda
JA, Zamora L, Xaus N, Clotet B, Leal M.
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive
and antiretroviral-experienced HIV-infected patients in Spain. AIDS. 1998 Jun
18;12(9):1015-20.
Goodenow M, Huet T, Saurin W, Kwok S, Sninsky J, Wain-Hobson S.
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and
preferred nucleotide substitutions. J Acquir Immune Defic Syndr. 1989;2(4):34452.
Gottlieb MS, Schroff R, Schrander HM, et al. Pneumocystis carinii pneumonia
and mucosal candidiasis in previously healthy homosexual men. N England J
Med. 1981; 305:1425-9.
Graham N, Peeters M, Verbiest W, et al. The virtual phenotype is an independent
th
predictor of clinical response. Program and abstracts of the 8 Conference on
Retroviruses and Oportunistic Infections. Chicago 2001. Abstract 524
a.Graziosi C, Pantaleo G, Demarest JF, Cohen OJ, Vaccarezza M, Butini L,
Montroni M, Fauci AS.
HIV-1 infection in the lymphoid organs.
AIDS. 1993 Nov;7 Suppl 2:S53-8.
b.Graziosi C, Pantaleo G, Butini L, Demarest JF, Saag MS, Shaw GM, Fauci AS.
Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA
synthesis during primary HIV-1 infection.
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6405-9.
Green WC. The molecular biology of human immunodeficiency virus type 1
infection. N Engl J Med. 1991; 324:08-17.
Groenink M, Andeweg AC, Fouchier RA, Broersen S, van der Jagt RC,
Schuitemaker H, de Goede RE, Bosch ML, Huisman HG, Tersmette M.
Phenotype-associated env gene variation among eight related human
immunodeficiency virus type 1 clones: evidence for in vivo recombination and
determinants of cytotropism outside the V3 domain.
J Virol. 1992 Oct;66(10):6175-80.
Gulick R, Mellors J, Havlir D et al. Potent and sustained antiretroviral activity of
indinavir, zidovudine and lamivudine. XI International Conference on AIDS.
Vancouver (Canada) 1996
183
Mireia Arnedo Valero
Referències
Gunthard H, Wong J, Ignacio C, et al. HIV replication and genotypic resistance in
blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;
72:2422-2428
Gupta P, Kingsley L, Armstrong J, Ding M, Cottrill M, Rinaldo C.
Enhanced expression of human immunodeficiency virus type 1 correlates with
development of AIDS.
Virology. 1993 Oct;196(2):586-95.
Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W,
Gebhard K, Staskus K, Zhang ZQ, Dailey PJ, Balfour HH Jr, Erice A, Perelson
AS. Quantitative image analysis of HIV-1 infection in lymphoid tissue.
Science. 1996 Nov 8;274(5289):985-9.
Haase AT.
Population biology of HIV-1 infection: viral and CD4+ T cell demographics and
dynamics in lymphatic tissues.
Annu Rev Immunol. 1999;17:625-56.
Haase AT. Transmission and propagation of SIV and HIV infection in vivo. 9th
Conference on Retroviruses and Opportunistic Infections. Seattle, USA. February
2002 [abstract L9].
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT,
Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan
TC.
A trial comparing nucleoside monotherapy with combination therapy in HIVinfected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS
Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996 Oct
10;335(15):1081-90.
Hammer S, Peeters M, Harrigan R, et al. Virtual phenotype is predictive of treatment
failure in treatment experienced patients. Program and abstracts of the 5th
International Workshop on HIV Drug Resistance and Treatment Strategies. Arizona
2001. Abstract 142
Hanh BH, Shaw GM, Arya SK, Popovic M, Gallo RC, Wong-Stall F. Molecular
cloning and caracterization of the HTLV-III virus associated with AIDS. Nature.
1984. 312, 166-169.
Hanh, BH, Gonda MA, Shaw GM, Popovic M, Hoxie JA, Gallo RC, Wong-Stall F.
Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III:
Different virus exhibit greatest divergence in their envelope. Proceedings of the
National Academy of Science of EEUU 1985.82, 4813-4817.
Hanh BH, Shaw GM, Taylor ME, Redfiel RR, Markham PD, Salahuddin SZ,
Wong-Stall F, Gallo RC, Parks ES, Parks WP. Genetic variation in HTLV-III/LAV
over time in patients with AIDS or at risk for AIDS. Science 1986. 232, 15481553.
Hanna GJ, D'Aquila RT.
Clinical use of genotypic and phenotypic drug resistance testing to monitor
antiretroviral chemotherapy.
184
Mireia Arnedo Valero
Referències
Clin Infect Dis. 2001 Mar 1;32(5):774-82. Epub 2001 Feb 28.
Harrigan PR, Whaley M, Montaner JS.
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.
AIDS. 1999 May 28;13(8):F59-62.
Harris M, Rachlis A, Shillington A et al. Long term supression of HIV in plasma
th
with a combination of two nucleosides and nevirapine. Abstract I86. 37 ICAAC,
Toronto, Ontario, Canada. 1997
Harrowe G, Cheng-Mayer C.
Amino acid substitutions in the V3 loop are responsible for adaptation to growth in
transformed T-cell lines of a primary human immunodeficiency virus type 1.
Virology. 1995 Jul 10;210(2):490-4.
Haseltine WA, Wong-Staal F. The molecular biology of the AIDS virus. Scientific
American 1988; 259:34-32
Haslett PA, Nixon DF, Shen Z, Larsson M, Cox WI, Manandhar R, Donahoe SM,
Kaplan G.
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a
cohort of chronically infected patients are associated with interruptions in anti-HIV
chemotherapy.
J Infect Dis. 2000 Apr;181(4):1264-72. Epub 2000 Apr 05.
Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dube
MP, Hwang J, Leedom JM, Tilles J, McCutchan JA; California Collaborative
Treatment Group.
A randomized study of the utility of human immunodeficiency virus RNA
measurement for the management of antiretroviral therapy.
Clin Infect Dis. 2001 Oct 1;33(7):1060-8. Epub 2001 Sep 05.
Havlir DV, Lange JM.
New antiretrovirals and new combinations.
AIDS. 1998;12 Suppl A:S165-74.
Havlir DV, Hellmann NS, Petrpoulos CJ, et al. Drug susceptibility in HIV infection
after viral rebound in patients receiving indinavir-cantaining regimens. JAMA
2000; 283:229-234
Hecht FM, Gran RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1
variant resistant to multiple RT and protease inhibitors. N Engl J Med 1998;
339:307-331
Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E,
Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM.
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1infected humans. Nat Med. 1999 Jan;5(1):83-9.
Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van
Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S,
Conant M, Bloor S, Kemp S, Larder B, Pauwels R.
185
Mireia Arnedo Valero
Referències
A rapid method for simultaneous detection of phenotypic resistance to inhibitors
of protease and reverse transcriptase in recombinant human immunodeficiency
virus type 1 isolates from patients treated with antiretroviral drugs.
Antimicrob Agents Chemother. 1998 Feb;42(2):269-76.
Hirsch MS, Richman DD.
The role of genotypic resistance testing in selecting therapy for HIV
JAMA. 2000 Oct 4;284(13):1649-50.
Ho DD, Moudgil T, Robin HS, Alam M, Wallace BJ, Mizrachi Y.
Human immunodeficiency virus type 1 in a seronegative patient with visceral
Kaposi's sarcoma and hypogammaglobulinemia.
Am J Med. 1989 Mar;86(3):349-51.
Ho DD.
HIV-1 dynamics in vivo.
J Biol Regul Homeost Agents. 1995 Jul-Sep;9(3):76-7.
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M.
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature.
1995 Jan 12;373(6510):123-6.
Ho DD.
Therapy of HIV infections: problems and prospects.
Bull N Y Acad Med. 1996 Summer;73(1):37-45.
Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S,
Nowak MA, Shaw GM, Bucy RP.
Constant mean viral copy number per infected cell in tissues regardless of high,
low, or undetectable plasma HIV RNA.
J Exp Med. 1999 May 17;189(10):1545-54.
Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R.
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked
to
phenotype-associated
changes
in
the
V3
loop.
J Virol. 2002 Apr;76(8):3852-64.
Hoffman TL, Doms RW.
Chemokines and coreceptors in HIV/SIV-host interactions.
AIDS. 1998;12 Suppl A:S17-26.
Imamichi H, Crandall KA, Natarajan V, Jiang MK, Dewar RL, Berg S, Gaddam A,
Bosche M, Metcalf JA, Davey RT Jr, Lane HC.
Human immunodeficiency virus type 1 quasi species that rebound after
discontinuation of highly active antiretroviral therapy are similar to the viral quasi
species present before initiation of therapy.
J Infect Dis. 2001 Jan 1;183(1):36-50. Epub 2000 Dec 08.
Imrie A, Beveridge A, Genn W, et al. Transmission of HIV-1 resistant to
nevirapine and zidovudine: Sydney primary HIV infection Study Group. J Infect
Dis 1997; 175:1502-1506
186
Mireia Arnedo Valero
Referències
Iribarren JA, Ramos JT, Guerra L, Coll O, de Jose MI, Domingo P, Fortuny C,
Miralles P, Parras F, Pena JM, Rodrigo C, Vidal R. Prevention of vertical
transmission and treatment of infection caused by the human immunodeficiency
virus in the pregnant woman. Recommendations of the Study Group for AIDS,
Infectious Diseases, and Clinical Microbiology, the Spanish Pediatric Association,
the National AIDS Plan and the Spanish Gynecology and Obstetrics Society.
Enferm Infecc Microbiol Clin. 2001 Aug-Sep;19(7):314-35.
Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H.
Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes
of primary HIV-1 isolates. Proc Natl Acad Sci U S A 1996 Dec 24;93(26):15382-7
Japour AJ, Welles S, D'Aquila RT, Johnson VA, Richman DD, Coombs RW,
Reichelderfer PS, Kahn JO, Crumpacker CS, Kuritzkes DR.
Prevalence and clinical significance of zidovudine resistance mutations in human
immunodeficiency virus isolated from patients after long-term zidovudine
treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology
Committee Resistance Working Group.
J Infect Dis. 1995 May;171(5):1172-9.
Jurriaans S, Dekker JT, de Ronde A.
HIV-1 viral DNA load in peripheral blood mononuclear cells from seroconverters
and long-term infected individuals.
AIDS. 1992 Jul;6(7):635-41.
Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R,
Koot M, Schuitemaker H, Goudsmit J.
The natural history of HIV-1 infection: virus load and virus phenotype independent
determinants of clinical course?
Virology. 1994 Oct;204(1):223-33.
Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD.
Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte
effector and memory responses decline after suppression of viremia with highly
active antiretroviral therapy.
J Virol. 1999 Aug;73(8):6721-8.
Kampinga GA, Simonon A, Van de Perre P, Karita E, Msellati P, Goudsmit J.
Primary infections with HIV-1 of women and their offspring in Rwanda: findings of
heterogeneity at seroconversion, coinfection, and recombinants of HIV-1
subtypes A and C.
Virology. 1997 Jan 6;227(1):63-76.
Kaplan JE, Masur H, Jaffe HW, Holmes KK.
Reducing the impact of opportunistic infections in patients with HIV infection. New
guidelines.
JAMA. 1995 Jul 26;274(4):347-8.
Katlama C.
Consequences for the management of cytomegalovirus.
AIDS. 1996 Nov;10 Suppl 1:S43-6.
187
Mireia Arnedo Valero
Referències
Katzenstein DA, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL,
Merigan TC.
Plasma viremia in human immunodeficiency virus infection: relationship to stage
of disease and antiviral treatment.
J Acquir Immune Defic Syndr. 1992;5(2):107-12.
Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J.
Longitudinal serum HIV RNA quantification: correlation to viral phenotype at
seroconversion and clinical outcome.
AIDS. 1996 Feb;10(2):167-73.
Keet IP, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, Apple RJ, Mann D,
Goedert JJ, Miedema F, Kaslow RA. Consistent associations of HLA class I and II
and transporter gene products with progression of human immunodeficiency virus
type 1 infection in homosexual men. J Infect Dis. 1999 Aug;180(2):299-309.
Kellam P, Larder BA. Recombinant virus assay: a rapid phenotypic assay for
assesment of drug susceptibility of HIV-1 isolates. Antimicrob Agents Chemother
1994; 38:23-30
Kellam P, Larder BA. Retroviral recombination can lead to linkage of reverse
transcriptase mutations that confer increased zidovudine resistance. J Virol. 1995
Kempf DJ, Rode RA, Xu Y, et al. The duration of viral supression during protease
inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the
nadir. AIDS 1998; 12:F9-F14
Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L,
Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw
GM, Saag MS.
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of
gp41-mediated virus entry. Nat Med. 1998 Nov;4(11):1302-7.
Kim R, Fromm F, Wandel C, et al. The drug transporter P-glycoprotein limits oral
absorption and brain entry of HIV-1 protease inhibitors. j Clin Invest 1998:
101:289-294.
Kinter AL, Umscheid CA, Arthos J, Cicala C, Lin Y, Jackson R, Donoghue E,
Ehler L, Adelsberger J, Rabin RL, Fauci AS. HIV envelope induces virus
expression from resting CD4+ T cells isolated from HIV-infected individuals in the
absence of markers of cellular activation or apoptosis. J Immunol. 2003 Mar
1;170(5):2449-55.
Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating
HIV infection. AIDS. 2001;15 Suppl 5:S171-81.
Knobel H, Carmona A, Grau S, Pedro-Botet J, Diez A.
Adherence and effectiveness of highly active antiretroviral therapy.
Arch Intern Med. 1998 Sep 28;158(17):1953.
Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, Coutinho
RA, Miedema F, Tersmette M.
188
Mireia Arnedo Valero
Referències
HIV-1 biological phenotype in long-term infected individuals evaluated with an
MT-2 cocultivation assay.
AIDS. 1992 Jan;6(1):49-54.
Korber BT, MacInnes K, Smith RF, Myers G.
Mutational trends in V3 loop protein sequences observed in different genetic
lineages
of
human
immunodeficiency
virus
type
1.
J Virol. 1994 Oct;68(10):6730-44.
Koup RA.
Virus escape from CTL recognition.
J Exp Med. 1994 Sep 1;180(3):779-82.
Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A,
Rosen C, Haseltine W, Sodroski J. Functional regions of the envelope
glycoprotein of human immunodeficiency virus type 1. Science. 1987 Sep
11;237(4820):1351-5.
Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS.
Dual infection of the central nervous system by AIDS viruses with distinct cellular
tropisms.
Science. 1987 May 15;236(4803):819-22.
Kozak SL, Platt EJ, Madani N, Ferro FE Jr, Peden K, Kabat D. CD4, CXCR-4,
and CCR-5 dependencies for infections by primary patient and laboratoryadapted
isolates
of
human
immunodeficiency
virus
type
1.
J Virol. 1997 Feb;71(2):873-82.
Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA,
Merigan TC.
Didanosine resistance in HIV-infected patients switched from zidovudine to
didanosine monotherapy.
Ann Intern Med. 1994 Aug 15;121(4):263-8.
Kramer A, Wiktor SZ, Fuchs D, Milstien S, Gail MH, Yellin FJ, Biggar RJ,
Wachter H, Kaufman S, Blattner WA, et al.
Neopterin: a predictive marker of acquired immune deficiency syndrome in
human immunodeficiency virus infection.
J Acquir Immune Defic Syndr. 1989;2(3):291-6.
Kure K, Llena JF, Lyman WD, Soeiro R, Weidenheim KM, Hirano A, Dickson
DW.
Human immunodeficiency virus-1 infection of the nervous system: an autopsy
study of 268 adult, pediatric, and fetal brains. Hum Pathol. 1991 Jul;22(7):700-10.
Kuritzkes DR, Bell S, Bakhtiari M.
Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant
syncytium-inducing isolate of HIV-1. AIDS. 1994 Jul;8(7):1017-9.
Lanier ER, Hellmann, Scott J et al. Determination of clinically relevant phenotypic
resistance “cutoff” for abacavir using the PhenoSense assay. Program and
abstracts of the 8th Conference on Retroviruses and Oportunistic Infections.
Chicago 2001. Abstract 254
189
Mireia Arnedo Valero
Referències
Lange JM, de Wolf F, Krone WJ, Danner SA, Coutinho RA, Goudsmit J.
Decline of antibody reactivity to outer viral core protein p17 is an earlier
serological marker of disease progression in human immunodeficiency virus
infection than anti-p24 decline.
AIDS. 1987 Sep;1(3):155-9.
Larder B, De Vroey V, Dehertogh P, et al. Predicting HIV-1 phenotypic resistance
from genotype using a large phenotype-genotype relational database. Abstract 59.
Antiviral Therapy 1999; 4 (sppl 1):41
Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y,
Freimuth WW, Tarpley G.
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
AIDS. 2000 Sep 8;14(13):1943-8.
b.Larder i col., Antiviral Therapy 2000; 5 Suppl. 3: 49 Abs 63
Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P,
Gregory T, Capon DJ. Delineation of a region of the human immunodeficiency
virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell.
1987 Sep 11;50(6):975-85.
Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological
failure on highly active antiretroviral therapy in HIV-1 patients: a prospective
cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8
Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are
substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-3601
Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA.
The significance of activation markers on CD8 lymphocytes in human
immunodeficiency syndrome: staging and prognostic value.
Clin Exp Immunol. 1992 Dec;90(3):376-82.
Levy JA, Hoffman AD, Framer SM, et al. Isolation of lymphocytophatic
retroviruses from San Francisco patients with AIDS. Science 1984; 225:840-2.
Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev
1993 Mar;57(1):183-289.
Levy JA, Hsueh F, Blackbourn DJ, Wara D, Weintrub PS.
CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected
and -uninfected children.
J Infect Dis. 1998 Feb;177(2):470-2.
Lew J, Reichelderfer P, Fowler M, Bremer J, Carrol R, Cassol S, Chernoff D,
Coombs R, Cronin M, Dickover R, Fiscus S, Herman S, Jackson B, Kornegay J,
Kovacs A, McIntosh K, Meyer W, Michael N, Mofenson L, Moye J, Quinn T, Robb
M, Vahey M, Weiser B, Yeghiazarian T.
Determinations of levels of human immunodeficiency virus type 1 RNA in plasma:
reassessment of parameters affecting assay outcome. TUBE Meeting Workshop
190
Mireia Arnedo Valero
Referències
Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization
in Pediatrics.
J Clin Microbiol. 1998 Jun;36(6):1471-9.
Lewin SR, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, Ho DD,
Markowitz M.
Use of real-time PCR and molecular beacons to detect virus replication in human
immunodeficiency virus type 1-infected individuals on prolonged effective
antiretroviral therapy.
J Virol. 1999 Jul;73(7):6099-103.
Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting
recovery in CD4 T-cell function and viral-load reduction after highly active
antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998 Jun
6;351(9117):1682-6.
Lifson AR, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M,
Hart CE, Hessol NA, Holmberg SD.
Long-term human immunodeficiency virus infection in asymptomatic homosexual
and bisexual men with normal CD4+ lymphocyte counts: immunologic and
virologic characteristics.
J Infect Dis. 1991 May;163(5):959-65.
Lifson AR, Hessol NA, Buchbinder SP, O'Malley PM, Barnhart L, Segal M, Katz
MH, Holmberg SD.
Serum beta 2-microglobulin and prediction of progression to AIDS in HIV
infection.
Lancet. 1992 Jun 13;339(8807):1436-40.
Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F.
HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a
protease inhibitor.
Lancet. 1998 Jul 18;352(9123):199-200.
Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R,
Walker B, Lori F.
Control of HIV despite the discontinuation of antiretroviral therapy.
N Engl J Med. 1999 May 27;340(21):1683-4.
Little SJ, Daar ES, D’Aquila RT, et al. Reduced antiretroviral drug susceptibility
among patients with primary HIV-1 infection. J Am Med Association 1999; 282:11421149
Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, Podzamczer D, Alberdi JC,
Martinez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera
E; Grupo de Estudio del SIDA 04/98. A randomized trial of the discontinuation of
primary and secondary prophylaxis against Pneumocystis carinii pneumonia after
highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio
del SIDA 04/98. N Engl J Med. 2001 Jan 18;344(3):159-67.
Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC.
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
Science. 1994 Nov 4;266(5186):801-5.
191
Mireia Arnedo Valero
Referències
Lori F, Jessen H, Lieberman J, Finzi D, Rosenberg E, Tinelli C, Walker B,
Siliciano RF, Lisziewicz J.
Treatment of human immunodeficiency virus infection with hydroxyurea,
didanosine, and a protease inhibitor before seroconversion is associated with
normalized immune parameters and limited viral reservoir.
J Infect Dis. 1999 Dec;180(6):1827-32.
Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, Wagner W, Greenhouse
J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J.
Control of SIV rebound through structured treatment interruptions during early
infection.
Science. 2000 Nov 24;290(5496):1591-3.
Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a
large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann
Intern Med. 1999 Jul 20;131(2):81-7.
Lukashov VV, Kuiken CL, Goudsmit J.
Intrahost human immunodeficiency virus type 1 evolution is related to length of
the immunocompetent period. J Virol. 1995 Nov;69(11):6911-6.
Lukashov VV, Goudsmit J.
HIV heterogeneity and disease progression in AIDS: a model of continuous virus
adaptation. AIDS. 1998;12 Suppl A:S43-52.
Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The
T4 gene encodes the AIDS virus receptor and is expressed in the immune system
and the brain. Cell. 1986 Nov 7;47(3):333-48.
Mansky LM, Temin HM.
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that
predicted from the fidelity of purified reverse transcriptase.
Virol. 1995 Aug;69(8):5087-94.
Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R.
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate
dehydrogenase, have profound and synergistic anti-HIV activity.
J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):362-70.
Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM,
Lanier ER, Shaw LM, Back D.
The addition of mycophenolate mofetil to antiretroviral therapy including abacavir
is associated with depletion of intracellular deoxyguanosine triphosphate and a
decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2002 Sep
1;31(1):45-9.
Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL,
Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell JM.
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a
prospective cohort study. Lancet. 2001 Feb 24;357(9256):592-8.
192
Mireia Arnedo Valero
Referències
a. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD,
Petropoulos CJ, Clotet B, Ruiz L.
Selection of drug-resistant HIV-1 mutants in response to repeated structured
treatment interruptions. AIDS. 2002 Apr 12;16(6):895-9.
b Martinez-Picado J, Frost SD, Izquierdo N, Morales-Lopetegi K, Marfil S, Puig
T, Cabrera C, Clotet B, Ruiz L.
Viral evolution during structured treatment interruptions in chronically human
immunodeficiency virus-infected individuals. J Virol. 2002 Dec;76(23):12344-8.
Masur H, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W,
Suffredini AF, Deyton L, Kovacs JA, Falloon J, et al.
CD4 counts as predictors of opportunistic pneumonias in human
immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Aug 1;111(3):22331
Maurer B, Flugel RM.
Genomic organization of the human spumaretrovirus and its relatedness to AIDS
and other retroviruses. AIDS Res Hum Retroviruses. 1988 Dec;4(6):467-73.
Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard
HW. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission
and disease progression. Nat Med. 1997 Mar;3(3):338-40.
McMichael AJ, Rowland-Jones SL.
Cellular immune responses to HIV.
Nature. 2001 Apr 19;410(6831):980-7.
Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, Gupta P.
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion.
Ann Intern Med. 1995 Apr 15;122(8):573-9.
Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA.
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science.
1996 May 24;272(5265):1167-70.
Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley
LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr.
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1
infection. Ann Intern Med. 1997 Jun 15;126(12):946-54.
Melnick D, Rosenthal J, Cameron M, et al. Impact of phenotypic antiretroviral
drug resistance testing on the response to salvage antiretroviral therapy (ART) in
heavily experienced patients. Program and abstracts of the 7th Conference on
Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San
Francisco, California. Abstract 786.
Menendez-Arias L, Mas A, Domingo E.
Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review)
Viral Immunol. 1998;11(4):167-81.
a. Meyaard L, Miedema F.
Programmed death of T cells in the course of HIV infection.
193
Mireia Arnedo Valero
Referències
Adv Exp Med Biol. 1995;374:115-20.
b. Meyaard L, Miedema F.
Programmed death of T cells in HIV infection: result of immune activation?
Curr Top Microbiol Immunol. 1995;200:213-21.
Meynard JL, Vray M, Morand-Joubert L, et al. Impact of treatment guided by
phenotypic or genotypic resistance tests on the response to antiretroviral therapy:
a randomized trial (NARVAL, ANRS 088). Antivir Ther. 2000;5(suppl 3):67.
Miedema F, Meyaard L, Koot M, Klein MR, Roos MT, Groenink M, Fouchier RA,
Van't Wout AB, Tersmette M, Schellekens PT, et al.
Changing virus-host interactions in the course of HIV-1 infection.
Immunol Rev. 1994 Aug;140:35-72.
Miró JM, Pumarola T, García F, Arnedo M, Vidal C, Lozano L. i col. Prevalence
of transmission of HIV-1 drug resistance mutations in patients with primary HIV-1
infection in Barcelona (Spain). XIII International AIDS Conference. Durban (South
Africa), 2000. Resumen TuPeB3270;
Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J,
Moye J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ.
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in
women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185
Team. N Engl J Med. 1999 Aug 5;341(6):385-93.
Mohri H, Shingh MK, Ching GTW et al. Quantitation of zidovudine-resistant HIV-1 in
the blood of treated and untreated patients. Proc Natl Acad Sci USA 1995; 373:123126.
Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV
protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766
Montaner JS, DeMasi R, Hill AM.
The effects of lamivudine treatment on HIV-1 disease progression are highly
correlated with plasma HIV-1 RNA and CD4 cell count.
AIDS. 1998 Mar 26;12(5):F23-8.
Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, Vo HT, Klein M, Tartaglia
J, Robinson HL, Rovinski B.
Induction of neutralizing antibodies and gag-specific cellular immune responses
to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus
macaques. J Virol. 2001 Jul;75(13):5879-90.
Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA.
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a
population level.
Science. 2002 May 24;296(5572):1439-43.
Moriuchi H, Moriuchi M, Mizell SB, Ehler LA, Fauci AS. In vitro reactivation of
human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after
bacterial stimulation. J Infect Dis. 2000 Jun;181(6):2041-4. Epub 2000 May 25.
194
Mireia Arnedo Valero
Referències
Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu
Rev Immunol. 1994 ; 12 :593-633.
Nájera I, Richman DD, Olivares I et al. Natural Occurrence of drug resistance
mutations in the reverse transcriptase of HIV-1 isolates. AIDS Res Hum Retrov
1994; 10:1475-1484
Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R,
Lopez-Galindez C, Domingo E.
Pol gene quasispecies of human immunodeficiency virus: mutations associated
with drug resistance in virus from patients undergoing no drug therapy.
J Virol. 1995 Jan;69(1):23-31.
Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, Agut H, Autran B, Katlama
C. HIV-1 rebound during interruption of highly active antiretroviral therapy has no
deleterious effect on reinitiated treatment. Comet Study Group.
AIDS. 1999 Apr 16;13(6):677-83.
Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J.
Stochastic processes strongly influence HIV-1 evolution during suboptimal
protease-inhibitor therapy. Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):144416.
Nowak MA, Bangham CR.
Population dynamics of immune responses to persistent viruses. Science. 1996
Apr 5;272(5258):74-9.
Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos
F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M,
Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents
infection by T-cell-line-adapted HIV-1. Nature. 1996 Aug 29;382(6594):833-5.
Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao
Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF,
McMichael AJ.
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral
RNA. Science. 1998 Mar 27;279(5359):2103-6.
Orenstein JM, Fox C, Tenner-Racz K, Racz P.
Is HIV found in the cytoplasm of dendritic cells? Am J Pathol. 1997
Oct;151(4):1173-6.
Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ,
Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang
L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M.
HIV-1-specific immune responses in subjects who temporarily contain virus
replication after discontinuation of highly active antiretroviral therapy.
J Clin Invest. 1999 Sep;104(6):R13-8.
Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K,
Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF.
Structured antiretroviral treatment interruptions in chronically HIV-1-infected
subjects.
195
Mireia Arnedo Valero
Referències
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13288-93. Epub 2001 Oct 30.
Ostrowski MA, Krakauer DC, Li Y, Justement SJ, Learn G, Ehler LA, Stanley
SK, Nowak M, Fauci AS. Effect of immune activation on the dynamics of human
immunodeficiency virus replication and on the distribution of viral quasispecies. J
Virol. 1998 Oct;72(10):7772-84.
Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK.
Distinct but related human immunodeficiency virus type 1 variant populations in
genital secretions and blood.
AIDS Res Hum Retroviruses. 1996 Jan 20;12(2):107-15.
Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA,
Sontag G, Sewell AK, Phillips RE.
Early highly active antiretroviral therapy for acute HIV-1 infection preserves
immune function of CD8+ and CD4+ T lymphocytes.
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7.
Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard
JM, Danner SA, Miedema F, Schellekens PT.
Biphasic kinetics of peripheral blood T cells after triple combination therapy in
HIV-1 infection: a composite of redistribution and proliferation.
Nat Med. 1998 Feb;4(2):208-14.
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA,
Aschman DJ, Holmberg SD.
Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. HIV Outpatient Study Investigators.
N Engl J Med. 1998 Mar 26;338(13):853-60.
Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, Fauci AS.
Lymphoid organs function as major reservoirs for human immunodeficiency virus.
Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9838-42.
Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein
JM, Kotler DP, Fauci AS.
HIV infection is active and progressive in lymphoid tissue during the clinically
latent stage of disease.
Nature. 1993 Mar 25;362(6418):355-8.
Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF,
Montefiori D, Orenstein JM, Fox C, Schrager LK, et al.Studies in subjects with
long-term
nonprogressive
human
immunodeficiency
virus
infection.
N Engl J Med. 1995 Jan 26;332(4):209-16.
Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M,
Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner
LJ.
Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T
cell responses in chronically infected persons after temporary treatment
interruption.
J Infect Dis. 2000 Sep;182(3):766-75. Epub 2000 Aug 17.
196
Mireia Arnedo Valero
Referències
Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR,
Mounzer K, Shull J, Montaner LJ. Lack of persistent drug-resistant mutations
evaluated within and between treatment interruptions in chronically HIV-1-infected
patients. AIDS. 2003 Nov 7;17(16):2337-43.
Parkin NT, Chappey C, Maroldo L, et al. Incidence and nature of phenotypegenotype discordance: Maximizing the utility of resistance testing. Program and
abstracts of the 9th Conference on Retroviruses and Oportunistic Infections.
Seattle 2002. Abstract 580
Patterson BK, Till M, Otto P, Goolsby C, Furtado MR, McBride LJ, Wolinsky SM.
Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in
situ hybridization and flow cytometry. Science. 1993 May 14;260(5110):976-9.
Peliska JA, Benkovic SJ.
Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse
transcriptase.
Science. 1992 Nov 13;258(5085):1112-8.
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD.
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral
generation time. Science. 1996 Mar 15;271(5255):1582-6
Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz
M, Ho DD. Decay characteristics of HIV-1-infected compartments during
combination therapy. Nature. 1997 May 8;387(6629):188-91.
b Perelson AS, Essunger P, Ho DD.
Dynamics of HIV-1 and CD4+ lymphocytes in vivo.
AIDS. 1997;11 Suppl A:S17-24.
Persaud D, Pierson T, Ruff C, Finzi D, Chadwick KR, Margolick JB, Ruff A,
Hutton N, Ray S, Siliciano RF. A stable latent reservoir for HIV-1 in resting
CD4(+) T lymphocytes in infected children. J Clin Invest. 2000 Apr;105(7):9951003.
Persaud D, Zhou Y, Siliciano JM, Siliciano RF.
Latency in human immunodeficiency virus type 1 infection: no easy answers.
J Virol. 2003 Feb;77(3):1659-65.
Peterson A, Seed B. Genetic analysis of monoclonal antibody and HIV binding
sites on the human lymphocyte antigen CD4. Cell. 1988 Jul 1;54(1):65-72.
Petrella M, Wainberg MA.
Might the M184V substitution in HIV-1 RT confer clinical benefit?
AIDS Rev. 2002 Oct-Dec;4(4):224-32.
Piatak M Jr, Yang LC, Luk KC, Lifson JD, Saag MS, Clark SJ, Kappes JC, Hahn
BH, Shaw GM.
Viral dynamics in primary HIV-1 infection.
Lancet. 1993 Apr 24;341(8852):1099.
Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F.
197
Mireia Arnedo Valero
Referències
Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human
immunodeficiency virus-infected dendritic cells and lymphocytes.
J Virol. 2002 Mar;76(5):2274-8.
Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, Picker
LJ.
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1
infection, but decline with prolonged viral suppression.
Nat Med. 1999 May;5(5):518-25.
Picker LJ.
Regulation of tissue-selective T-lymphocyte homing receptors during the virgin to
memory/effector cell transition in human secondary lymphoid tissues.
Am Rev Respir Dis. 1993 Dec;148(6 Pt 2):S47-54.
Pierson T, McArthur J, Siliciano RF.
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral
immune responses and antiretroviral therapy.
Annu Rev Immunol. 2000;18:665-708.
Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF.
Intrinsic stability of episomal circles formed during human immunodeficiency virus
type 1 replication.
J Virol. 2002 Apr;76(8):4138-44.
Piscitelli SC, Wells MJ, Metcalf JA, Baseler M, Stevens R, Davey RT Jr.
Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIVinfected patients. Pharmacotherapy. 1996 Sep-Oct;16(5):754-9.
Plana M, Garcia F, Gallart T, Miro JM, Gatell JM.
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active
antiretroviral treatment in early HIV-1 disease. Immunology Study Group of
Spanish EARTH-1 Study. Lancet. 1998 Oct 10;352(9135):1194-5.
Plana M, Garcia F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ,
Barcelo JJ, Vidal C, Cruceta A, Miro JM, Gatell JM.
Immunological benefits of antiretroviral therapy in very early stages of
asymptomatic chronic HIV-1 infection. AIDS. 2000 Sep 8;14(13):1921-33.
Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells nonproductively
infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a
molecular model for latency. Cell. 1990 Jun 29;61(7):1271-6.
Polis MA, Masur H.
Predicting the progression to AIDS. Am J Med. 1990 Dec;89(6):701-5.
Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, Paxton WA.
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major
determinant
of
CCR5
and
CXCR4
coreceptor
utilization.
J Biol Chem. 2001 Apr 20;276(16):13433-41.
198
Mireia Arnedo Valero
Referències
Pozni A, Gazzard D, Churchill D, et al. British HIV Association (BHIVA)
guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
London 2000; http://www.aidsmap.com
Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, islation, and
continuous production of cytopathic retroviruses (HTLV-III) from patients with
AIDS and pre-AIDS. Science. 1984; 224: 497-500.
Powderly WG, Sesion M, Conant M et al. The efficacy of viracept in pivotal phase
I/II double-blind randomized controlled trials as monotherapy and in combination with
D4T or AZT/3TC. 4th Conference on Retroviruses and Opportunistic Infections.
Washington DC (USA) 1997
Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science
1988; 242:1168-71
Price DA, O’callaghan CA, Whelan JA, Easterbrook PJ, Phillips RE. Cytotoxic
T lymphocytes and viral evolution in primary HIV-1 infection. Clin Sci (Lond)
1999, 97(6): 707-18.
Psallidopoulos MC, Schnittman SM, Thompson LM 3rd, Baseler M, Fauci AS,
Lane HC, Salzman NP.
Integrated proviral human immunodeficiency virus type 1 is present in CD4+
peripheral blood lymphocytes in healthy seropositive individuals.
J Virol. 1989 Nov;63(11):4626-31.
Puig T, Perez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, Gomez-Cano
M, Stuyver L, Zamora L, Alvarez C, Leal M, Clotet B, Soriano V.
Prevalence of genotypic resistance to nucleoside analogues and protease
inhibitors in Spain. The ERASE-2 Study Group.
AIDS. 2000 Apr 14;14(6):727-32.
Quinn TC, Kline RL, Halsey N, Hutton N, Ruff A, Butz A, Boulos R, Modlin JF.
Early diagnosis of perinatal HIV infection by detection of viral-specific IgA
antibodies.
JAMA. 1991 Dec 25;266(24):3439-42.
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F,
Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of
human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med.
2000 Mar 30;342(13):921-9.
Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA,
Perelson AS, Markowitz M, Ho DD.
The decay of the latent reservoir of replication-competent HIV-1 is inversely
correlated with the extent of residual viral replication during prolonged antiretroviral therapy.
Nat Med. 2000 Jan;6(1):82-5.
Ravot E, Tambussi G, Jessen H, Tinelli C, Lazzarin A, Lisziewicz J, Lori F.
Effects of hydroxyurea on T cell count changes during primary HIV infection.
AIDS. 2000 Mar 31;14(5):619-22.
199
Mireia Arnedo Valero
Referències
Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW,
Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F,
Lange JM.
Maintenance therapy after quadruple induction therapy in HIV-1 infected
individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Lancet. 1998 Jul 18;352(9123):185-90.
Reinhart TA, Rogan MJ, Viglianti GA, Rausch DM, Eiden LE, Haase AT.
A new approach to investigating the relationship between productive infection and
cytopathicity in vivo.
Nat Med. 1997 Feb;3(2):218-21.
Rezza G, Lazzarin A, Angarano G, Sinicco A, Pristera R, Ortona L, Barbanera M,
Gafa S, Tirelli U, Salassa B, et al.
The natural history of HIV infection in intravenous drug users: risk of disease
progression in a cohort of seroconverters.
AIDS. 1989 Feb;3(2):87-90.
Richman DD.
Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human
immunodeficiency virus.
Am J Med. 1990 May 21;88(5B):8S-10S.
Richman DD, Havlir D,Corbeil J et al. Nevirapine resistance mutations of HIV-1
selected during therapy. J Virol 1994; 68:1660-1666
Richman DD.
How drug resistance arises.
Sci Am. 1998 Jul;279(1):88.
Rizzardi GP, Vaccarezza M, Capiluppi B, Tambussi G, Lazzarin A, Pantaleo G.
Cyclosporin A in combination with HAART in primary HIV-1 infection.
J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):79-81.
Rodriguez-Rosado R, Briones C, Soriano V.
Introduction of HIV drug-resistance testing in clinical practice.
AIDS. 1999 Jun 18;13(9):1007-14.
Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA,
Walker BD.
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
Science. 1997 Nov 21;278(5342):1447-50.
Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL,
Robbins GK, D'Aquila RT, Goulder PJ, Walker BD.
Immune control of HIV-1 after early treatment of acute infection.
Nature. 2000 Sep 28;407(6803):523-6.
Rubio R, Berenguer J, Miro JM, Antela A, Iribarren JA, Gonzalez J, Guerra L,
Moreno S, Arrizabalaga J, Clotet B, Gatell JM, Laguna F, Martinez E, Parras F,
Santamaria JM, Tuset M, Viciana P. Recommendations of the Spanish AIDS
Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral
200
Mireia Arnedo Valero
Referències
REFERÈNCIES
st
Adams B, Holte S, Randolph T, Banks HT. STI control of HIV infection. 1 SIAM
Conference on the Life Sciences. Boston, USA. March 2002.
Alcami J, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F,
Noriega AR, Hay RT, Harrich D, Gaynor RB, et al.
Absolute dependence on kappa B responsive elements for initiation and Tatmediated amplification of HIV transcription in blood CD4 T lymphocytes.
EMBO J. 1995 Apr 3;14(7):1552-60.
Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge
RL ,and al. Cellular immune responses and viral diversity in individuals treated
during acute and early HIV-1 infection. J Exp Med 2001, 15; 193(2): 169-80.
Allain JP, Laurian Y, Paul DA, Senn D.
Serological markers in early stages of human immunodeficiency virus infection in
haemophiliacs.
Lancet. 1986 Nov 29;2(8518):1233-6.
Allain JP, Frommel D, Bosser C, Gazengel C, Larrieu MJ, Sultan Y.
The role of HIV infectivity and composition of factor VIII concentrates on the
immunity of haemophiliacs positive for HIV antibodies.
Vox Sang. 1987;53(1):37-43.
Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo
EM.
Replicative capacity of human immunodeficiency virus from patients with varying
severity of HIV infection.
Lancet. 1986 Sep 20;2(8508):660-2.
Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre
P, Leibowitch J.
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis
and function in advanced HIV disease.
Science. 1997 Jul 4;277(5322):112-6.
Autran B, Carcelain G.
AIDS. Boosting immunity to HIV--can the virus help?
Science. 2000 Nov 3;290(5493):946-9.
Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral
management based on plasma genotypic antiretroviral resistance testing in
patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community
Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-F93.
Bagglioni M, Dewald B, Moser B. Interleukin 8 and related chemotactic cytokines
CXC and CC chemokines. Adv Immunol 1994; 55:97-179.
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J,
Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W,
Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for
169
Mireia Arnedo Valero
Referències
treatment in adult patients with human immunodeficiency virus infection in 2002.
Enferm Infecc Microbiol Clin. 2002 Jun-Jul;20(6):244-303.
Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, Negredo E,
Sirera G, Tural C, Clotet B.
Structured treatment interruption in chronically HIV-1 infected patients after longterm viral suppression.
AIDS. 2000 Mar 10;14(4):397-403.
Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S,
Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish
Lipodystrophy Group.
Antiretroviral treatment simplification with nevirapine in protease inhibitorexperienced patients with hiv-associated lipodystrophy: 1-year prospective followup of a multicenter, randomized, controlled study.
J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36.
b Ruiz L, Carcelain G, Martinez-Picado J, Frost S, Marfil S, Paredes R, Romeu J,
Ferrer E, Morales-Lopetegi K, Autran B, Clotet B.
Saag MS, Hahn BH, Gibbons J, et al. Extensive variation of HIV-1 in vivo. Nature
1988; 334:440-444
Saag MS, Crain MJ, Decker WD, Campbell-Hill S, Robinson S, Brown WE,
Leuther M, Whitley RJ, Hahn BH, Shaw GM.
High-level viremia in adults and children infected with human immunodeficiency
virus: relation to disease stage and CD4+ lymphocyte levels.
J Infect Dis. 1991 Jul;164(1):72-80.
Saag MS.
Evolving understanding of the immunopathogenesis of HIV.
AIDS Res Hum Retroviruses. 1994 Aug;10(8):887-92.
Sabino EC, Delwart E, Lee TH, Mayer A, Mullins JI, Busch MP.
Identification of low-level contamination of blood as basis for detection of human
immunodeficiency virus (HIV) DNA in anti-HIV-negative specimens. J Acquir
Immune Defic Syndr. 1994 Aug;7(8):853-9.
Salvatori F, Masiero S, Giaquinto C, Wade CM, Brown AJ, Chieco-Bianchi L, De
Rossi A.
Evolution of human immunodeficiency virus type 1 in perinatally infected infants
with
rapid
and
slow
progression
to
disease.
J Virol. 1997 Jun;71(6):4694-706.
Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D.
HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker
of risk for progression to AIDS. Ann Intern Med. 1995 Nov 1;123(9):641-8
Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic
features of primary HIV infection. Ann Intern Med. 1996 Aug 15;125(4):257-64.
201
Mireia Arnedo Valero
Referències
Shafer RW, Gonzales MJ, and Brun-Vezinet. Online comparison of HIV-1 drug
resistance algorithms identifies rates and causes of discordant interpretation.
Antiviral Ther 2001: 6(suppl 1):101
Schellekens PT, Tersmette M, Roos MT, Keet RP, de Wolf F, Coutinho RA,
Miedema F.
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates
with HIV-1 phenotype.
AIDS. 1992 Jul;6(7):665-9.
Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P,
Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori
DC, Rieber EP, Letvin NL, Reimann KA.
Control of viremia in simian immunodeficiency virus infection by CD8+
lymphocytes. Science. 1999 Feb 5;283(5403):857-60.
Schmidt B, Walter H, Schwingel E, et al. Comparison of different interpretation
systems for genotypic HIV-1 drug resistance data. Antiviral Ther 2001; 6(suppl
1):101
Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari
F, Fox CH, Salzman NP, Fauci AS.
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains
expression of CD4.
Science. 1989 Jul 21;245(4915):305-8.
Schnittman SM, Greenhouse JJ, Psallidopoulos MC, Baseler M, Salzman NP,
Fauci AS, Lane HC.
Increasing viral burden in CD4+ T cells from patients with human
immunodeficiency virus (HIV) infection reflects rapidly progressive
immunosuppression and clinical disease. Ann Intern Med. 1990 Sep
15;113(6):438-43.
Schnittman SM, Singer KH, Greenhouse JJ, Stanley SK, Whichard LP, Le PT,
Haynes BF, Fauci AS.
Thymic microenvironment induces HIV expression. Physiologic secretion of IL-6
by thymic epithelial cells up-regulates virus expression in chronically infected
cells. J Immunol. 1991 Oct 15;147(8):2553-8.
Schockmel GA, Yerly S, Perrin L.
Detection of low HIV-1 RNA levels in plasma.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):179-83.
Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in
resistance to nucleoside-based antiretroviral drugs. Nat Med 1999; 5:1048-1051
Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P,
Danner SA, Mulder J, Loveday C, Christopherson C, et al.
Rapid changes in human immunodeficiency virus type 1 RNA load and
appearance of drug-resistant virus populations in persons treated with lamivudine
(3TC).
J Infect Dis. 1995 Jun;171(6):1411-9.
202
Mireia Arnedo Valero
Referències
Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG,
Bartlett JA, Nixon DF.
Emergence of drug-resistant HIV-1 variants in patients undergoing structured
treatment interruptions. AIDS. 2002 Nov 22;16(17):2342-4.
Sereti I, Lane HC.
Immunopathogenesis of human immunodeficiency virus: implications for immunebased therapies. Clin Infect Dis. 2001 Jun 15;32(12):1738-55. Epub 2001 May
16.
Shi C, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of
HIV-1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents
Chemother 1997: 41:2781-2785
Secretaría del Plan Nacional Sobre el SIDA (SPNS). La resistencia a los
fármacos antirretrovirales: Utilización de los test en la práctica asistencial. Madrid
2000; http://www.msc.es/sida/asistencia/resistencias.htm
Shafer RW, Winters MA, Palmer S, Merigan TC.
Multiple concurrent reverse transcriptase and protease mutations and multidrug
resistance of HIV-1 isolates from heavily treated patients.
Ann Intern Med. 1998 Jun 1;128(11):906-11.
Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan
H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI.
Consistent viral evolutionary changes associated with the progression of human
immunodeficiency virus type 1 infection.
J Virol. 1999 Dec;73(12):10489-502.
Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy
RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS,
Bova C, Ellison RT 3rd, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B,
Shaunak S, Stevenson M.
Persistence of episomal HIV-1 infection intermediates in patients on highly active
anti-retroviral therapy.
Nat Med. 2000 Jan;6(1):76-81.
Sharkey ME, Stevenson M.
Two long terminal repeat circles and persistent HIV-1 replication.
Curr Opin Infect Dis. 2001 Feb;14(1):5-11.
Shioda T, Oka S, Xin X, Liu H, Harukuni R, Kurotani A, Fukushima M, Hasan
MK, Shiino T, Takebe Y, Iwamoto A, Nagai Y.
In vivo sequence variability of human immunodeficiency virus type 1 envelope
gp120: association of V2 extension with slow disease progression.
J Virol. 1997 Jul;71(7):4871-81.
Shioda T, Levy JA, Cheng-Mayer C.
Small amino acid changes in the V3 hypervariable region of gp120 can affect the
T-cell-line and macrophage tropism of human immunodeficiency virus type 1.
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9434-8.
203
Mireia Arnedo Valero
Referències
Siegal FP, Lopez C Hammer GS, et al., Severe acquired immunodeficiency
syndrome in male homosexuals, manifested by chronic perianal ulcerative
Herpes simplex lesions. N England J Med. 1981; 305: 1439-43.
Siliciano JD, Siliciano RF.
Latency and viral persistence in HIV-1 infection.
J Clin Invest. 2000 Oct;106(7):823-5.
Sodroski J, Rosen C, Wong-Stall F, Salahuddin SZ, et al., Trans-acting
transcriptional regulation of human T-cell leukaemia virus type III long terminal
repeat. Science 1895; 227:171-173.
Spector SA, Kennedy C, McCutchan JA, Bozzette SA, Straube RG, Connor JD,
Richman DD.
The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24
antigen levels as a virologic marker. J Infect Dis. 1989 May;159(5):822-8.
Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD.
The importance of nef in the induction of human immunodeficiency virus type 1
replication
from
primary
quiescent
CD4
lymphocytes.
J Exp Med. 1994 Jan 1;179(1):115-23.
Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of
human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in
vitro. J Virol. 1995 May;69(5):2977-88.
Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM,
Feinberg MB.
Activation of virus replication after vaccination of HIV-1-infected individuals.
J Exp Med. 1995 Dec 1;182(6):1727-37.
Stein M, O'Sullivan P, Wachtel T, Fisher A, Mikolich D, Sepe S, Fort G,
Carpenter C, Skowron G, Mayer K.
Causes of death in persons with human immunodeficiency virus infection.
Am J Med. 1992 Oct;93(4):387-90
Stellbrink HJ, Zoller B, Fenner T, Lichtenberg G, van Lunzen J, Albrecht H,
Thiele HG, Greten H.
Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an
only transient interruption by treatment. AIDS. 1996 Jul;10(8):849-57.
Staszewski S, Miller V, Sabin C, Berger A, Hill AM, Phillips AN.
Rebound of HIV-1 viral load after suppression to very low levels.
AIDS. 1998 Dec 3;12(17):2360.
Staszewski S, Morales J, Tashima KT, et al. Efavirenz plus zidovudine and
lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in
the treatment of HIV-1 infection in adults. New Engl J Med 1999; 341:1865-1873
204
Mireia Arnedo Valero
Referències
Takehisa J, Osei-Kwasi M, Ayisi NK, Hishida O, Miura T, Igarashi T, Brandful J,
Ampofo W, Netty VB, Mensah M, Yamashita M, Ido E, Hayami M.
Phylogenetic analysis of HIV type 2 in Ghana and intrasubtype recombination in
HIV type 2. AIDS Res Hum Retroviruses. 1997 May 1;13(7):621-3.
Takehisa J, Zekeng L, Ido E, Yamaguchi-Kabata Y, Mboudjeka I, Harada Y,
Miura T, Kaptu L, Hayami M.
Human immunodeficiency virus type 1 intergroup (M/O) recombination in
cameroon. J Virol. 1999 Aug;73(8):6810-20.
Tamalet C, Lafeuillade A, Tourres C, Yahi N, Vignoli C, De Micco P.
Inefficacy of neutralizing antibodies against autologous lymph-node HIV-1
isolates in patients with early-stage HIV infection. AIDS. 1994 Mar;8(3):388-9.
Teeuwsen VJ, Schalken JJ, van der Groen G, van de Akker R, Goudsmit J,
Osterhaus AD.
An inhibition enzyme immunoassay using a human monoclonal antibody (K14)
reactive with gp41 of HIV-1 for the serology of HIV-1 infections. AIDS. 1991
Jul;5(7):893-6
Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, Huisman
HG, Miedema F.
Differential syncytium-inducing capacity of human immunodeficiency virus
isolates: frequent detection of syncytium-inducing isolates in patients with
acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
J Virol. 1988 Jun;62(6):2026-32.
Tersmette M, Miedema F.
Interactions between HIV and the host immune system in the pathogenesis of
AIDS. AIDS. 1990;4 Suppl 1:S57-66.
Tindall B, Cooper DA.
Primary HIV infection: host responses and intervention strategies. AIDS. 1991
Jan;5(1):1-14.
Torre D, Pugliese A, Orofino G.
Effect of highly active antiretroviral therapy on ischemic cardiovascular disease in
patients with HIV-1 infection. Clin Infect Dis. 2002 Sep 1;35(5):631-2.
Tortajada C, Garcia F, Plana M, Gallart T, Maleno MJ, Miro JM, Gatell JM.
Comparison of T-cell subsets' reconstitution after 12 months of highly active
antiretroviral therapy initiated during early versus advanced states of HIV disease.
J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):296-305.
Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker
BD, Hirsch MS, Rosenberg ES, D'Aquila RT.
Antiretroviral resistance associated with supervised treatment interruptions in
treated acute HIV infection. AIDS. 2003 May 2;17(7):1086-9.
Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert
advice: the Havana trial. AIDS. 2002;16:209-218.
205
Mireia Arnedo Valero
Referències
US Dept of Health and Human Services. Guidelines for the use of antiretroviral
agents in HIV-infected adults and adolescents. Washington, DC: US Dept of
Health and Human Services; February 4, 2002. Published at:
http://hivatis.org/trtgdlns.html.
Vento S, Di Perri G, Garofano T, Concia E, Bassetti D.
Pneumocystis carinii pneumonia during primary HIV-1 infection.
Lancet. 1993 Jul 3;342(8862):24-5.
Vidal C, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T,
Miro JM, Pumarola T, Gatell JM.
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected
patients failing initial therapy with stavudine, didanosine and nevirapine. Antivir
Ther. 2002 Dec;7(4):283-7.
Wain-Hobson S.
HIV genome variability in vivo. AIDS. 1989;3 Suppl 1:S13-8. Review.
Wain-Hobson S.
Human immunodeficiency virus type 1 quasispecies in vivo and ex vivo.
Curr Top Microbiol Immunol. 1992;176:181-93. Review.
Wain-Hobson S.
The fastest genome evolution ever described: HIV variation in situ.
Curr Opin Genet Dev. 1993 Dec;3(6):878-83.
Wain-Hobson S.
Running
the
gamut
of
Trends Microbiol. 1996 Apr;4(4):135-41. Review.
retroviral
variation.
Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD,
Bonhoeffer S, Nowak MA, Hahn BH, et al.
Viral dynamics in human immunodeficiency virus type 1 infection.
Nature. 1995 Jan 12;373(6510):117-22.
Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM,
Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD,
Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J,
Kwok S, Crumpacker CS.
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA
levels in patients with advanced HIV-1 disease and with little or no prior
zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.J
Infect Dis. 1996 Oct;174(4):696-703.
Whitcomb JM, Kumar R, Hughes SH.
Sequence of the circle junction of human immunodeficiency virus type 1:
implications
for
reverse
transcription
and
integration.
J Virol. 1990 Oct;64(10):4903-6.
Wildemann B, Haas J, Ehrhart K etal. In vivo comparison of zidovudine
resistance mutations in blood and CSF of HIV-1 infected patients both
simultaneously in plasma but also between different body compartments such as
blood and CSF. Neurology 1993; 43:2659-2663
206
Mireia Arnedo Valero
Referències
Wolfs TF, Zwart G, Bakker M, Goudsmit J.
HIV-1 genomic RNA diversification following sexual and parenteral virus
transmission. Virology. 1992 Jul;189(1):103-10.
Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL,
Kunstman KJ, Furtado MR, Munoz JL.
Selective transmission of human immunodeficiency virus type-1 variants from
mothers to infants. Science. 1992 Feb 28;255(5048):1134-7.
Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ,
Furtado MR, Cao Y, Ho DD, Safrit JT.
Adaptive evolution of human immunodeficiency virus-type 1 during the natural
course of infection. Science. 1996 Apr 26;272(5261):537-42.
Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD.
In vivo compartmentalization of human immunodeficiency virus: evidence from
the
examination
of
pol
sequences
from
autopsy
tissues.
J Virol. 1997 Mar;71(3):2059-71.
Wodarz D. Helper-dependent vs. helper-independent CTL responses in HIV
infection: implications for drug therapy and resistance. J Theor Biol. 2001 Dec
7;213(3):447-59.
Wong JK, Hezareh M, Gunthard H, et al. Recovery of replication-competent HIV
despite prolonged supression of plasma viremia. Science 1997; 278:1291-129
Xiao L, Rudolph DL, Owen SM, Spira TJ, Lal RB.Adaptation to promiscuous
usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1
disease progression. AIDS 1998 Sep 10;12(13):F137
Yagi MJ, Chu FN, Jiang JD, Wallace J, Mason P, Liu Y, Carafa J, Bekesi JG.
Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in
human immunodeficiency virus type-1 infection.
Clin Immunol Immunopathol. 1992 May;63(2):126-34.
Yamaguchi Y, Gojobori T.
Evolutionary mechanisms and population dynamics of the third variable envelope
region
of
HIV
within
single
hosts.
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1264-9.
Yang OO, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD. Impacts of
avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol.
2003 Oct 1;171(7):3718-24.
Yokomaku Y, Miura H, Tomiyama H, Kawana-Tachikawa A, Takiguchi M, Kojima
A, Nagai Y, Iwamoto A, Matsuda Z, Ariyoshi K. Impaired processing and
presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape
mechanisms from CTL immune pressure in human immunodeficiency virus type 1
infection. J Virol. 2004 Feb;78(3):1324-32.
207
Mireia Arnedo Valero
Referències
Yusa K, Kavlick MF, Mitsuya H. HIV-1 acquires resistance to multiple classes of
antiviral drugs through recombination. 4th Conference on Retroviruses and
Opportunistic Infections. Whasington DC (USA) 1997
Yusim K, Kesmir C, Gaschen B, Addo MM, Altfeld M, Brunak S, Chigaev A,
Detours V, Korber BT. Clustering patterns of cytotoxic T-lymphocyte epitopes in
human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune
evasion on HIV-1 global variation.J Virol. 2002 Sep;76(17):8757-68.
Yuste E, Lopez-Galindez C, Domingo E.
Unusual distribution of mutations associated with serial bottleneck passages of
human immunodeficiency virus type 1.J Virol. 2000 Oct;74(20):9546-52.
Xiao L, Rudolph DL, Owen SM, Spira TJ, Lal RB.
Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo
correlates with HIV-1 disease progression. AIDS. 1998 Sep 10;12(13):F137-43.
Zack JA, Cann AJ, Lugo JP, Chen IS.
HIV-1 production from infected peripheral blood T cells after HTLV-I induced
mitogenic stimulation. Science. 1988 May 20;240(4855):1026-9
Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS.
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a
labile, latent viral structure. Cell. 1990 Apr 20;61(2):213-22.
Zhang L, He T, Huang Y, Chen Z, Guo Y, Wu S, Kunstman KJ, Brown RC, Phair
JP, Neumann AU, Ho DD, Wolinsky SM.
Chemokine coreceptor usage by diverse primary isolates of human
immunodeficiency virus type 1.
J Virol. 1998 Nov;72(11):9307-12
Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A,
Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD.
Quantifying residual HIV-1 replication in patients receiving combination
antiretroviral therapy. N Engl J Med. 1999 May 27;340(21):1605-13.
Zhang L, Chung C, Hu BS, He T, Guo Y, Kim AJ, Skulsky E, Jin X, Hurley A,
Ramratnam B, Markowitz M, Ho DD.
Genetic characterization of rebounding HIV-1 after cessation of highly active
antiretroviral therapy. J Clin Invest. 2000 Oct;106(7):839-45.
Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is
caused by mutations in the protease gene and in its gag substrate cleavage sites. J
Virol 1997; 71:6662-6670
Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD.
Genotypic and phenotypic characterization of HIV-1 patients with primary
infection. Science. 1993 Aug 27;261(5125):1179-81.
Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD
Genetic characterization of human immunodeficiency virus type 1 in blood and
genital secretions: evidence for viral compartmentalization and selection during
sexual transmission. J Virol. 1996 May;70(5):3098-107.
208
Fly UP